Thyme Care Raises $125M in Series C+ to Expand Value-Based Oncology Care

Thyme Care, a leading value-based care enabler for oncology, announced today that it has raised $125 million in a Series C+ funding round. The investment was led by Morgan Health, with participation from Humana, Concord Health Partners, a16z Bio + Health, Town Hall Ventures, CVS Health Ventures, HealthQuest Capital, Foresite Capital, AlleyCorp, and Frist Cressey Ventures.

About Thyme Care

Thyme Care collaborates with payers and providers to transform the experience and outcomes for individuals living with cancer. The company partners with health plans, employers, and risk-bearing providers to assume accountability for enhanced care quality, improved health outcomes, and reduced total cost of care.

Thyme Care's approach combines a technology-enabled Care Team with seamless integration into more than 800 oncologists in Thyme Care Oncology Partners. This hybrid collaborative care model guides and supports the entire patient journey, empowering oncologists nationwide through purpose-built technology, advanced data analytics, and virtual patient engagement.

Funding Details

The new capital will support Thyme Care's mission to enable the shift to value-based care in oncology. The company is a founding member of CancerX and is backed by leading investors.

For more information, visit www.thymecare.com.